One in five people will develop skin cancer at some point in their lives, with more than three million cases in over two million people diagnosed annually in the U.S. Most patients are diagnosed with non-melanoma skin cancer (NMSC). Basal cell carcinoma is the most common type of NMSC, while squamous cell carcinoma is the second most common form. The majority of lesions are located on sun-exposed areas like the face, back of hands and neck. According to the NCCN guidelines3, radiation therapy is a primary treatment option for NMSC, or a secondary option in case of positive margins post-surgery.

The Xoft® Electronic Brachytherapy (eBx®) System® provides a non-surgical treatment option for non-melanoma skin cancer. Unlike alternative brachytherapy procedures, which use radioactive isotopes, the Xoft System utilizes an isotope-free miniature X-ray source. The X-ray source delivers high dose radiation to the target area. Xoft eBx® can be delivered in a minimally shielded environment allowing the physician to remain in the room throughout treatment.

During Xoft eBx®, a small, lightweight surface applicator is placed directly on the target lesion where the radiation is to be delivered.


Courtesy of Ajay Bhatnagar, MD, Cancer Treatment Services, Arizona 

Surgical excision is the most common skin cancer treatment, but in certain patients, primary or postoperative radiotherapy can be an ideal alternative, with good to excellent cosmetic4 results.

Xoft eBx® provides an additional treatment option for skin cancer with a variety of benefits including:

• targeted treatment resulting in good to excellent cosmesis4
• painless treatment using a small, lightweight applicator
• isotope-free radiation source requires minimal shielding
• fewer visits compared to external beam therapy
• better monitoring with presence of therapist

See patient brochure for additional important information